

**Request for Applications
Award for Research into Calpain 3 and
Limb Girdle Muscular Dystrophy Type 2A/R1 (LGMD2A/R1)**

Synopsis:

Coalition to Cure Calpain 3 provides funding for research and translational projects to expand the understanding of calpain 3 and LGMD2A/R1 to enable development of therapeutic approaches for this disease.

This award is intended for both US and non-US based academic and biopharmaceutical organizations. This award cannot be used for indirect costs and overhead charges.

Grant focus areas:

C3 is actively soliciting grant proposals for research related to understanding LGMD2A/R1 in the context of developing a therapeutic including:

- Alteration of LGMD2A/R1 disease course by identification and testing of agents that protect or restore degenerating and/or dysfunctional skeletal muscle
- Identification and validation of therapeutic targets in LGMD2A/R1, inclusive of bioinformatics and artificial intelligence approaches
- Disease mechanisms and/or pathogenesis of LGMD2A/R1
- Innovation in LGMD2A clinical trial readiness including the development of outcome assessments
- As appropriate, applicants may consider utilization of [Capn3-null mouse strains available from The Jackson Laboratories](#)

To be eligible to apply for this grant, applicants must:

- Hold a Ph.D., M.D., D.Sc., or equivalent degree (e.g., D.O.)
- Be a professional or faculty member (professor, associate professor, or assistant professor) at a research institution or be a head of research/project lead at a biopharmaceutical organization
- Assume both administrative and financial responsibility for the grant
- Have access to institutional resources necessary to conduct the proposed research project
- Have previous experience and a successful track record of conducting research grant projects on time and budget

Note: Academic-industry partnerships will be given special consideration

Letter of Intent Instructions:

The first step in the grant application is to submit a Letter of Intent (LOI). LOIs should be one to two pages and include a budget and timeline that present the project's milestones, a brief description of the methodology, and the rationale for the impact of the project. LOIs should be emailed to Coalition to Cure Calpain 3 Scientific Director Dr. Jennifer Levy (jennifer@curecalpain3.org) by September 1, 2021. Applicants with accepted LOIs will be invited to submit a full proposal, which will be due by November 1, 2021.